StreetInsider.com News Articles

Form 8-K ARTELO BIOSCIENCES, INC. For: Aug 26

Thu, 27 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260827/26985473.html

Form 8-K ARTELO BIOSCIENCES, INC. For: Aug 26

Thu, 27 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260827/26985473.html

Artelo Biosciences executes 1-for-9 reverse stock split

Thu, 27 Aug 2026 08:02:00 -0400

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company, announced a 1-for-9 reverse stock split of its common stock, with shares beginning to trade on a split-adjusted basis on the Nasdaq Capital Market at market open on Aug. 31, 2026.

As a result of the split, every nine shares of issued and outstanding common stock will be automatically combined into one share. The company stated the reverse split is intended to increase the per-share price of its common stock to improve marketability and liquidity.

No fractional shares will be issued. Stockholders who would otherwise be entitled to a fractional share will automatically

Artelo Biosciences executes 1-for-9 reverse stock split

Thu, 27 Aug 2026 08:02:00 -0400

No fractional shares will be issued. Stockholders who would otherwise be entitled to a fractional share will automatically

Artelo Biosciences Announces Reverse Stock Split

Thu, 27 Aug 2026 08:00:00 -0400

SOLANA BEACH, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced a 1-for-9 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock”). The Company’s Common Stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open on August 31, 2026. The Reverse Split is being effected in order to increase the price per share of the

Artelo Biosciences Announces Reverse Stock Split

Thu, 27 Aug 2026 08:00:00 -0400

Artelo Biosciences Announces Reverse Stock Split

Thu, 27 Aug 2026 08:00:00 -0400

Artelo Biosciences Announces Reverse Stock Split

Thu, 27 Aug 2026 08:00:00 -0400

Form 10-Q/A ARTELO BIOSCIENCES, INC. For: Jun 30

Thu, 20 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260820/26956571.html

Form 10-Q/A ARTELO BIOSCIENCES, INC. For: Jun 30

Thu, 20 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260820/26956571.html

Artelo Biosciences wins Japan patent allowance for ART27.13

Thu, 20 Aug 2026 08:52:14 -0400

Artelo Biosciences, Inc. (NASDAQ: ARTL) announced that the Japanese Patent Office has issued a notice of allowance with a Decision to Grant for the company's patent application covering the intended commercial formulation of ART27.13, a peripherally selective dual cannabinoid agonist.

The allowed claims in Japan protect compositions of ART27.13 dispersed in polyethylene glycol. The claims are consistent with those previously allowed in the United States and Europe, and all three jurisdictions are expected to provide patent protection through 2041.

ART27.13 was originally developed by AstraZeneca and fully licensed to Artelo in 2019. It is currently being evaluated in two Phase 2 clinical

Artelo Biosciences wins Japan patent allowance for ART27.13

Thu, 20 Aug 2026 08:52:14 -0400

ART27.13 was originally developed by AstraZeneca and fully licensed to Artelo in 2019. It is currently being evaluated in two Phase 2 clinical

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

Thu, 20 Aug 2026 08:52:00 -0400

SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company’s patent application covering the intended commercial formulation of ART27.13, Artelo’s peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials.

The allowed claims in Japan protect compositions of ART27.13 dispersed in

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

Thu, 20 Aug 2026 08:52:00 -0400

The allowed claims in Japan protect compositions of ART27.13 dispersed in

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

Thu, 20 Aug 2026 08:52:00 -0400

The allowed claims in Japan protect compositions of ART27.13 dispersed in

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

Thu, 20 Aug 2026 08:52:00 -0400

The allowed claims in Japan protect compositions of ART27.13 dispersed in

Artelo Biosciences gets U.S. patent allowance for ART27.13 drug

Mon, 17 Aug 2026 08:52:20 -0400

Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering the intended commercial formulation of its investigational drug ART27.13, according to a press release.

The allowed claims cover compositions of ART27.13 dispersed in polyethylene glycol, including the company's intended commercial formulation. The patent protection is expected to extend through 2041.

ART27.13 is a peripherally selective cannabinoid agonist currently being evaluated in two Phase 2 studies: the CAReS trial for cancer-related anorexia and the DREAM study in patients with glaucoma or ocular hypertension.

Interim Phase 2 data from the CAReS

Artelo Biosciences gets U.S. patent allowance for ART27.13 drug

Mon, 17 Aug 2026 08:52:20 -0400

The allowed claims cover compositions of ART27.13 dispersed in polyethylene glycol, including the company's intended commercial formulation. The patent protection is expected to extend through 2041.

Interim Phase 2 data from the CAReS

Artelo Biosciences gets U.S. patent allowance for ART27.13 drug

Mon, 17 Aug 2026 08:52:20 -0400

The allowed claims cover compositions of ART27.13 dispersed in polyethylene glycol, including the company's intended commercial formulation. The patent protection is expected to extend through 2041.

Interim Phase 2 data from the CAReS

Artelo Biosciences gets U.S. patent allowance for ART27.13 drug

Mon, 17 Aug 2026 08:52:20 -0400

The allowed claims cover compositions of ART27.13 dispersed in polyethylene glycol, including the company's intended commercial formulation. The patent protection is expected to extend through 2041.

Interim Phase 2 data from the CAReS

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

Mon, 17 Aug 2026 08:52:00 -0400

The Patent Claims are for the Intended Commercial Formulation of ART27.13

Expected to Extend Patent Protection for ART27.13 through 2041

SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a U.S. patent application covering the intended commercial formulation of ART27.13, the Company’s peripherally selective cannabinoid agonist currently being evaluated

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

Mon, 17 Aug 2026 08:52:00 -0400

The Patent Claims are for the Intended Commercial Formulation of ART27.13

Expected to Extend Patent Protection for ART27.13 through 2041

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

Mon, 17 Aug 2026 08:52:00 -0400

The Patent Claims are for the Intended Commercial Formulation of ART27.13

Expected to Extend Patent Protection for ART27.13 through 2041

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

Mon, 17 Aug 2026 08:52:00 -0400

The Patent Claims are for the Intended Commercial Formulation of ART27.13

Expected to Extend Patent Protection for ART27.13 through 2041

Form SCHEDULE 13G/A ARTELO BIOSCIENCES, INC. Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26926078.html